首页> 美国卫生研究院文献>Clinical and Experimental Vaccine Research >Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
【2h】

Assessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults

机译:接种 CoronaVac 疫苗的印度尼西亚成人抗 SARS-CoV-2 受体结合域抗体评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.
机译:调查了 CoronaVac 在学术场所的印度尼西亚成年人中的免疫原性。两剂 CoronaVac 疫苗诱导了抗 SARS-CoV-2 受体结合域 (RBD) 抗体滴度为 9.1 至 151.9 U/mL 的严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 幼稚成人的完全血清转化。中位数低于在 2019 年轻度冠状病毒病康复成人中观察到的值(38.7 vs. 114.5 U/mL)。尽管如此,93.6% 的接种疫苗的成年人,与 76.5% 的康复成人相比,显示出高于临界值的抑制率,以阻断 RBD-血管紧张素转换酶 2 结合。这表明两剂 CoronaVac 具有免疫原性,并且可能对印度尼西亚成年人具有保护作用。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号